CSF3 and diffuse large B-cell lymphoma: A phase 1 dose escalation study of BAY 1143572 in combination with granulocyte colony-stimulating factor in patients with advanced malignancies (ie, gastric cancer, triple negative breast cancer, or diffuse large B-cell lymphoma [DLBCL]; NCT01938638) has been completed, but results are yet to be reported.